Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4006
Name bladder urothelial carcinoma
Definition A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder urothelial carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 mutant Infigratinib bladder urothelial carcinoma sensitive detail...
FGFR3 mutant Dovitinib bladder urothelial carcinoma sensitive detail...
FGFR3 S249C Dovitinib bladder urothelial carcinoma sensitive detail...
FGFR3 mutant Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 R248C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 S249C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 Y373C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 G370C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 A391E Fexagratinib bladder urothelial carcinoma predicted - sensitive detail...
HRAS Q61R Tipifarnib bladder urothelial carcinoma predicted - sensitive detail...
HRAS V29Cfs*19 Tipifarnib bladder urothelial carcinoma predicted - sensitive detail...
PIK3CA M1043I PIK3CA amp Everolimus bladder urothelial carcinoma predicted - sensitive detail...
FGFR3 Y373C Anlotinib + Sintilimab bladder urothelial carcinoma predicted - sensitive detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor bladder urothelial carcinoma decreased response detail...
CDKN2A del unspecified immune checkpoint inhibitor bladder urothelial carcinoma decreased response detail...
FGFR3 act mut Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 S249C PIK3CA E545K Erdafitinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 S249C PIK3CA E545K Futibatinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 S249C FGFR3 V553M Erdafitinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 Y373C FGFR3 N540K FGFR3 V555L FGFR3 L608V Futibatinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 Y373C Pemigatinib bladder urothelial carcinoma predicted - sensitive detail...
FGFR3 S249C TSC1 Q830* Erdafitinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 S249C TSC1 S561fs Erdafitinib bladder urothelial carcinoma predicted - sensitive detail...
FGFR3 S249C FGFR3 E587Q FGFR3 amp PIK3CA E726K TSC1 S561fs Erdafitinib bladder urothelial carcinoma predicted - resistant detail...
FGFR3 S249C Pembrolizumab + Pemigatinib bladder urothelial carcinoma predicted - sensitive detail...
FGFR3 S249C R3-altibody bladder urothelial carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed USA 1
NCT01108055 Phase II Paclitaxel + Pazopanib Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Completed USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01215136 Phase II Everolimus Paclitaxel First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated USA 0
NCT01326871 Phase Ib/II ALT-801 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Completed USA 0
NCT01438112 Phase II Valrubicin Mitomycin C CG0070 Interferon gamma Gemcitabine Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) Terminated USA 0
NCT01625260 Phase Ib/II ALT-801 ALT-801 + Gemcitabine A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Terminated USA 0
NCT01780545 Phase II Apatorsen Docetaxel Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Completed USA 0
NCT01916109 Phase II Carboplatin + Gemcitabine + Panitumumab Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Terminated USA 0
NCT02009332 Phase Ib/II Sirolimus Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Completed USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Completed USA | CAN 0
NCT02108652 Phase II Atezolizumab A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT02122172 Phase II Afatinib Afatinib in Advanced Refractory Urothelial Cancer Terminated USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Terminated USA | FRA | ESP | CAN 1
NCT02197897 Phase II Tamoxifen Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors Completed USA 0
NCT02236195 Phase II Mocetinostat Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Completed USA 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ROU | POL | ITA | BGR 0
NCT02256436 Phase III Pembrolizumab A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Completed 0
NCT02300610 Phase I Cisplatin + Gemcitabine Enzalutamide Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed USA 0
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | TUR | SWE | SVN | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS 6
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA | NLD | FRA 1
NCT02324582 Phase I Pembrolizumab MK-3475/BCG in High Risk Superficial Bladder Cancer Completed USA 0
NCT02334527 Phase II Palbociclib Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy Terminated USA 0
NCT02335424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) Completed 0
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Completed USA 0
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Active, not recruiting USA 0
NCT02365818 Phase II CG0070 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure Completed USA 0
NCT02387996 Phase II Nivolumab A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer Completed USA | SWE | POL | ITA | FIN | ESP | DEU | CZE | BEL | AUS 1
NCT02401542 Phase Ib/II Docetaxel + Vofatamab Vofatamab Docetaxel Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21) Terminated USA | TUR | SWE | ITA | GBR | ESP | CZE 2
NCT02426125 Phase III Ramucirumab Docetaxel A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Completed USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS 6
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Completed USA 0
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Completed USA | GBR | FRA | ESP | DEU 1
NCT02449239 Phase III Oportuzumab monatox Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Completed USA | CAN 0
NCT02450331 Phase III Atezolizumab A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) Terminated USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUS 7
NCT02451423 Phase II Atezolizumab Study of MPDL3280A in Bladder Cancer Completed USA 0
NCT02459119 Phase II Regorafenib Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02496208 Phase I Ipilimumab Cabozantinib + Nivolumab Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Active, not recruiting USA 0
NCT02500121 Phase II Pembrolizumab Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer Completed USA 0
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS 7
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Completed USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02567409 Phase II Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Completed USA 0
NCT02589717 FDA approved Atezolizumab An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy Approved for marketing USA 0
NCT02608125 Phase I PRN1371 A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma Terminated USA | ESP 0
NCT02612194 Phase II Crizotinib LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Terminated USA 0
NCT02619253 Phase Ib/II Pembrolizumab + Vorinostat Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Completed USA 0
NCT02621151 Phase II Pembrolizumab Gemcitabine Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Active, not recruiting USA 0
NCT02625961 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Recruiting USA | TUR | NLD | ITA | FRA | FIN | ESP | BRA | AUS 2
NCT02632409 Phase III Nivolumab A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma Active, not recruiting USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02657486 Phase 0 Infigratinib BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder Active, not recruiting USA 0
NCT02662062 Phase II Cisplatin + Pembrolizumab Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (PCR-MIB) Active, not recruiting AUS 0
NCT02690558 Phase II Cisplatin + Gemcitabine + Pembrolizumab Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy Active, not recruiting USA 0
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Terminated USA 0
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | NLD | FRA | CAN 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT02792192 Phase Ib/II Atezolizumab + BCG solution Atezolizumab Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants Terminated USA 0
NCT02807636 Phase III Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy Completed USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS 17
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting USA 0
NCT02844816 Phase II Atezolizumab Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer Active, not recruiting USA | CAN 0
NCT02845323 Phase II Urelumab Nivolumab + Urelumab Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder Active, not recruiting USA 0
NCT02853305 Phase III Pembrolizumab Carboplatin + Cisplatin + Gemcitabine Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Completed 0
NCT02872714 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Completed USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL 1
NCT02891161 Phase Ib/II Durvalumab Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Terminated USA 0
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT02901548 Phase II Durvalumab Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Terminated USA 0
NCT02925533 Phase I Pembrolizumab + Vofatamab Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Terminated USA 0
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Completed USA | ESP | CAN 0
NCT02989584 Phase Ib/II Atezolizumab + Cisplatin + Gemcitabine A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03022825 Phase II BCG solution + Nogapendekin alfa inbakicept QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03093922 Phase II Atezolizumab + Cisplatin + Gemcitabine A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03106610 Phase I Nivolumab Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy Terminated USA 0
NCT03132922 Phase I afamitresgene autoleucel MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03150836 Phase II Durvalumab Durvalumab + Tremelimumab Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Withdrawn USA 0
NCT03170960 Phase Ib/II Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 0
NCT03171493 Phase I MV-NIS Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy Completed USA 0
NCT03237780 Phase II Atezolizumab Atezolizumab + Eribulin Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT03258593 Phase I Durvalumab + Oportuzumab monatox Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Completed USA 0
NCT03272217 Phase II Atezolizumab + Bevacizumab Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Terminated USA 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA | GBR | AUS 1
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Completed USA 0
NCT03324282 Phase II Cisplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma (GCISAVE) Terminated FRA 0
NCT03359239 Phase I Atezolizumab + PGV 001 Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Completed USA 0
NCT03361865 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Completed USA | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT03374488 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Completed USA | TUR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS 4
NCT03379909 Phase II Metformin Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (TROJAN) Recruiting NLD 0
NCT03397394 Phase II Rucaparib Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) Terminated USA | ITA | GBR | FRA | ESP | DEU 0
NCT03410693 Phase II Docetaxel Vinflunine Paclitaxel Rogaratinib Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) Completed USA | SWE | SVK | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS 8
NCT03421652 Phase II Nivolumab Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy Completed USA 0
NCT03425201 Phase Ib/II Cabozantinib + Niraparib Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) Completed ESP 0
NCT03451331 Phase II Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Completed USA 0
NCT03459846 Phase II Durvalumab + Olaparib Durvalumab A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) Active, not recruiting USA | ESP | CAN 4
NCT03472274 Phase II Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) Completed ESP 0
NCT03473730 Phase I Daratumumab Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03473756 Phase Ib/II Atezolizumab Atezolizumab + Rogaratinib Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) Completed USA | ITA | FRA | ESP | DEU | AUT 2
NCT03498196 Phase Ib/II Avelumab A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Terminated USA 0
NCT03502681 Phase I Avelumab + Eribulin A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients Terminated USA 0
NCT03502785 Phase Ib/II Atezolizumab + INO-5401 + INO-9012 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Active, not recruiting USA 0
NCT03513952 Phase II Atezolizumab + CYT107 Atezolizumab Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Completed USA 0
NCT03517956 Phase I Copanlisib + Rogaratinib Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) Completed USA | ESP | DEU | BEL 2
NCT03518320 Phase I Gemcitabine + Nivolumab Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Terminated USA 0
NCT03519256 Phase II Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) Terminated USA | NLD | ITA | GBR | FRA | ESP | CAN | BRA | AUS | ARG 5
NCT03520231 Phase II Carboplatin + Cisplatin + Denosumab + Gemcitabine Carboplatin + Cisplatin + Gemcitabine Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Completed CAN 0
NCT03520491 Phase II Ipilimumab + Nivolumab Nivolumab A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Recruiting USA 0
NCT03529890 Phase II Nivolumab Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) Unknown status DEU 0
NCT03532451 Phase I Lirilumab + Nivolumab Nivolumab Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) Completed USA 0
NCT03557918 Phase II Tremelimumab Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Completed USA 0
NCT03575013 Phase I Avelumab + Docetaxel A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer Active, not recruiting USA 0
NCT03601455 Phase II Durvalumab + Tremelimumab Durvalumab Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03617913 Phase II Avelumab + Cisplatin + Fluorouracil + Mitomycin C Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Completed USA 0
NCT03620435 Phase II Atezolizumab Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer Unknown status CAN 0
NCT03628716 Phase II Atezolizumab + CV301 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN | AUS 0
NCT03674424 Phase II Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) Active, not recruiting FRA | BEL 0
NCT03682068 Phase III Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) Active, not recruiting USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BGR | AUS | ARG 9
NCT03697850 Phase II Atezolizumab Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar) Active, not recruiting FRA 0
NCT03711032 Phase III BCG solution + Pembrolizumab BCG solution Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Active, not recruiting USA | TUR | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS 10
NCT03732677 Phase III Cisplatin + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS 7
NCT03737123 Phase II Atezolizumab + Carboplatin + Gemcitabine Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated USA 0
NCT03768570 Phase II Durvalumab Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer Active, not recruiting GBR | ESP | CAN 0
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Completed USA 0
NCT03775265 Phase III Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03799835 Phase III Atezolizumab + BCG solution BCG solution Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) Active, not recruiting FRA | ESP | BEL 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | ISR | FRA | ESP | CAN | BEL | AUS 4
NCT03824691 Phase II Cabozantinib + Durvalumab hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA) Unknown status ITA 0
NCT03854721 Phase I VAX014 A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer Completed USA 0
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT03869190 Phase Ib/II Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) Active, not recruiting USA | GRC | GBR | FRA | ESP 2
NCT03898180 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Completed USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG 5
NCT03912818 Phase II Cisplatin + Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Carboplatin + Durvalumab + Gemcitabine Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Terminated USA 0
NCT03914794 Phase II Pemigatinib A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Recruiting USA 0
NCT03915405 Phase I Avelumab + KHK2455 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Terminated USA | ESP 0
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03935347 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Withdrawn USA 0
NCT03978624 Phase II Pembrolizumab Entinostat + Pembrolizumab Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Active, not recruiting USA 0
NCT03980041 Phase II Nivolumab Eganelisib + Nivolumab Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Completed USA | POL | ITA | FRA | ESP | CZE 1
NCT04004442 Phase II AVB-S6-500 + Avelumab Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN) Active, not recruiting USA 0
NCT04040725 Phase II Rogaratinib Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Withdrawn 0
NCT04045613 Phase Ib/II Derazantinib Atezolizumab + Derazantinib Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02) Completed USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUT | AUS 1
NCT04064190 Phase II Durvalumab + Vactosertib Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Not yet recruiting USA 0
NCT04066595 Phase II Cabozantinib Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (CabUC) Terminated DEU 0
NCT04073160 Phase I Durvalumab Durvalumab + Tremelimumab TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) Withdrawn USA 0
NCT04109092 Phase I E7766 A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 Withdrawn USA 0
NCT04134000 Phase I Atezolizumab + BCG solution Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE) Active, not recruiting ESP 0
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting USA | NLD | FRA | DNK | BEL 0
NCT04164082 Phase II Gemcitabine + Pembrolizumab Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Recruiting USA 2
NCT04165317 Phase III BCG solution + PF-06801591 BCG solution Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer. (B8011006) Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT04179110 Phase II Pembrolizumab + Ramucirumab Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor Withdrawn USA 0
NCT04216290 Phase II Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study Active, not recruiting USA 0
NCT04276376 Phase II Atezolizumab + Rucaparib Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Suspended FRA 0
NCT04289779 Phase II Atezolizumab + Cabozantinib Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE) (ABATE) Active, not recruiting USA 0
NCT04294277 Phase II Pemigatinib Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS) Terminated ITA 0
NCT04349280 Phase I Bintrafusp alfa A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer Terminated USA | NLD | FRA | ESP | CAN 0
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed USA 0
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Completed USA | GBR 0
NCT04430036 Phase II Balstilimab + Cisplatin + Gemcitabine + Zalifrelimab AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Terminated USA 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Active, not recruiting USA | FRA 0
NCT04501094 Phase II Bintrafusp alfa A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Terminated USA 0
NCT04506554 Phase II Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Active, not recruiting USA 0
NCT04602078 Phase II Atezolizumab + Cisplatin + Gemcitabine Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA) Completed ESP 0
NCT04608045 Phase I CPX-POM Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors Completed USA 0
NCT04610671 Phase I CG0070 + Nivolumab Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Active, not recruiting USA 0
NCT04624399 Phase II Atezolizumab Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer (ABACUS-2) Recruiting GBR 0
NCT04630730 Phase II BCG solution Atezolizumab + Cisplatin + Gemcitabine Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC Recruiting CHE 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Active, not recruiting USA 0
NCT04660344 Phase III Atezolizumab A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) Active, not recruiting USA | TUR | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | ARG 9
NCT04678362 Phase II Avelumab + Talazoparib TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR) Recruiting FRA 0
NCT04690699 Phase Ib/II PVSRIPO + unspecified PD-1 antibody LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Terminated USA 0
NCT04701918 Phase II Pembrolizumab Pembrolizumab And Cryoablation In Urothelial Carcinoma Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Recruiting USA | ISR | GBR | CAN 0
NCT04724018 Phase I Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy Sacituzumab Govitecan Plus EV in Metastatic UC Active, not recruiting USA 0
NCT04779151 Phase II Dostarlimab-gxly + Niraparib Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) Suspended FRA 0
NCT04813107 Phase Ib/II APL-1202 + Tislelizumab Tislelizumab A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE) Unknown status USA 1
NCT04848519 Phase II Pembrolizumab + Propranolol Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer Recruiting USA 0
NCT04871529 Phase II Avelumab + Carboplatin + Gemcitabine Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Suspended USA 0
NCT04876313 Phase II Nab-paclitaxel + Nivolumab An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo) Recruiting ITA 0
NCT04879329 Phase II Disitamab vedotin Disitamab vedotin + Pembrolizumab A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG 2
NCT04919512 Phase II Cetrelimab + TAR-200 Cetrelimab A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) Active, not recruiting USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL 1
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04953104 Phase II Nivolumab Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Recruiting USA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Recruiting USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS 4
NCT04963153 Phase I Enfortumab vedotin-ejfv + Erdafitinib Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Recruiting USA | CAN 0
NCT04972253 Phase I Infigratinib Phase I BLASST-3 Trial ((BLASST)-3) Withdrawn 0
NCT05077709 Phase II IO102-IO103 + Pembrolizumab IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Active, not recruiting USA | GBR | ESP 0
NCT05085977 Phase I TARA-002 Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1) Active, not recruiting USA | ROU 2
NCT05085990 Phase I TARA-002 Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1) Completed USA 0
NCT05092958 Phase III Avelumab + Cabozantinib Avelumab Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Active, not recruiting USA | CAN 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05120622 Phase Ib/II Durvalumab + Tremelimumab Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau) Withdrawn CAN 0
NCT05137262 Phase II Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Cisplatin + Doxorubicin + Methotrexate + Vinblastine A PHASE II MULTICENTER STUDY OF CHEMOTHERAPY VERSUS CHEMOTHERAPY PLUS DURVALUMAB (MEDI 4736) IN PATIENTS WITH LYMPH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER Recruiting USA 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT05200988 Phase II Mitomycin C Ipilimumab + Nivolumab Capecitabine Fluorouracil Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade) Active, not recruiting NLD 0
NCT05203913 Phase II Cisplatin + Nab-paclitaxel + Nivolumab Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer (CNN-BC) Recruiting ITA 0
NCT05219435 Phase II Ipilimumab + Nivolumab Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) Recruiting ESP 0
NCT05239624 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Recruiting USA 0
NCT05316155 Phase I Erdafitinib Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Recruiting USA | NLD | ESP | DEU 1
NCT05406713 Phase II Pembrolizumab Pembrolizumab in MIBC Recruiting USA 0
NCT05562830 Phase Ib/II VLS-101 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) Active, not recruiting USA | ISR | ESP | DNK | AUS 2
NCT05564416 Phase II Erdafitinib Atezolizumab + Erdafitinib Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Withdrawn 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05894447 Phase I Naptumomab estafenatox + Pembrolizumab Obinutuzumab Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers Withdrawn USA 0
NCT05911295 Phase III Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting USA | ITA | ISR | FRA | ESP | CAN | BRA | AUS | ARG 5
NCT05943106 Phase III BCG solution + Durvalumab BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO) Recruiting USA 0
NCT05987241 Phase II Nivolumab Nivolumab + Relatlimab Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Recruiting USA 0
NCT06059547 Phase II Nivolumab CTL-002 + Nivolumab Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Recruiting ITA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 2
NCT06225596 Phase II Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG 5
NCT06263153 Phase II Durvalumab + Futibatinib Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Recruiting USA 0
NCT06394570 Phase Ib/II Enfortumab vedotin-ejfv Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (STAR-EV) Recruiting USA 0
NCT06434350 Phase Ib/II Enfortumab vedotin-ejfv Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) Suspended USA 0
NCT06528483 Phase II Sacituzumab govitecan-hziy + Zimberelimab Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer (preSAVE) Not yet recruiting ITA 0
NCT06630247 Phase I XL495 A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06660654 Phase II Raludotatug deruxtecan A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Not yet recruiting USA 0
NCT06682728 Phase II Nivolumab + Sacituzumab govitecan-hziy Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence Recruiting USA 0